The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND. Antipsychotic-induced weight gain (AIWG) and other adverse metabolic effects represent serious side effects faced by many patients with psychosis that can lead to numerous comorbidities and which reduce the lifespan. While the pathophysiology of AIWG remains poorly understood, numerous studies have reported a positive association between AIWG and the therapeutic benefit of antipsychotic medications. OBJECTIVES. To review the literature to 1) determine if AIWG is consistently associated with thera-peutic benefit and 2) investigate which variables may mediate such an association. DATA SOURCES. MEDLINE, Google Scholar, Cochrane Database and PsycINFO databases were searched for articles containing all the following exploded MESH terms : schizophrenia [AND] antipsy-chotic agents/neuroleptics [AND] (weight gain [OR] lipids [OR] insulin [OR] leptin) [AND] treatment outcome. Results were limited to full-text, English journal articles. RESULTS. Our literature search uncovered 31 independent studies which investigated an AIWG-therapeutic benefit association with a total of 6063 enrolled individuals diagnosed with schizophrenia or another serious mental illness receiving antipsychotic medications. Twenty-two studies found a positive association while, 10 studies found no association and one study reported a negative association. Study variables including medication compliance, sex, ethnicity, or prior antipsychotic exposure did not appear to consistently affect the AIWG-therapeutic benefit relationship. In contrast, there was some evidence that controlling for baseline BMI/psychopathology, duration of treatment and specific agent studied (i.e. olanzapine (OLZ) or clozapine (CLZ)) strengthened the relationship between AIWG and therapeutic benefit. LIMITATIONS. There were limitations of the reviewed studies in that many had small sample sizes, and/ or were retrospective. The heterogeneity of the studies also made comparisons difficult and publi-cation bias was not controlled for. CONCLUSIONS. An AIWG-therapeutic benefit association may exist and is most likely to be ob-served in OLZ and CLZ-treated patients. The clinical meaningfulness of this association remains unclear and weight gain and other metabolic comorbidities should be identified and treated to the same targets as the general population. Further research should continue to explore the links between therapeutic benefit and metabolic health with emphasis on both pre-clinical work and well-designed prospective clinical trials examining metabolic parameters associated, but also occurring independently to AIWG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Common variants near MC4R are associated with fat mass, weight and risk of obesity
The Prostate, L., Loos, R. J. F., KORA, Study, N. H., Initiative, D. G., Study, T. S., The Wellcome Trust Case Control Consortium, FUSION, Lindgren, C. M., Li, S., et al. (2008) · Nature Genetics · doi:10.1038/ng.140 · Cited by 1,325 · cited 2×
“MC4R remains the leading gene associated with monogenic obesity (Loos et al., 2008) and insulin resistance (Chambers et al., 2008).”
BackgroundPillinger, T., McCutcheon, R. A., Vano, L., Mizuno, Y., Arumuham, A., Hindley, G., Beck, K., Natesan, S., Efthimiou, O., Cipriani, A., et al. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30416-x · Cited by 1,090
Correll, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050 · cited 4×
“, ziprasidone, and aripiprazole), are associated with significant weight gain in antipsychotic antipsychotic-naïve individuals (Correll, 2009; Patel et al., 2009; Bak et al., 2014).”
BackgroundInfluentialAlmost All Antipsychotics Result in Weight Gain: A Meta-Analysis
Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094112 · Cited by 490
Chiu, S.-L., Chen, C.-M., & Cline, H. T. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.014 · Cited by 425
Laursen, T. M., Wahlbeck, K., Hällgren, J., Westman, J., Ösby, U., Alinaghizadeh, H., Gissler, M., & Nordentoft, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067133 · Cited by 313 · cited 1×
“Notably, patients with schizophrenia have significantly reduced lifespans compared to the general population—by 11–20 years—which is attributable to their higher risk of death from cardiovascular causes (Hennekens and Newcomer, 2007; Laursen et al., 2013; Kredentser et al., 2014).”
BackgroundTeff, K. L., Rickels, M. R., Grudziak, J., Fuller, C., Nguyen, H.-L., & Rickels, K. (2013) · Diabetes · doi:10.2337/db13-0430 · Cited by 195 · cited 2×
“In healthy controls treated with antipsychotics, there is evidence to suggest that OLZ increases serum insulin levels and simultaneously induces peripheral insulin resistance, even prior to any weight gain (Hardy et al., 2007; Teff et al., 2013).”
BackgroundSchwarz, E., Guest, P. C., Steiner, J., Bogerts, B., & Bahn, S. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.3 · Cited by 91 · cited 17×
“Of these studies, 14 found an association between adverse metabolic effects and therapeutic benefit (Planansky, 1958; Planansky and Heilizer, 1959; Holden and Holden, 1970; Leadbetter et al., 1992; Bai et al., 1999; Czobor et al., 2002; Garyfallos et al., 2003; Lane et al., 2003; Meltzer et al., 2003; Hung et al., 201…”
BackgroundResultInfluentialThe microbiome-gut-brain axis: implications for schizophrenia and antipsychotic induced weight gain
Kanji, S., Fonseka, T. M., Marshe, V. S., Sriretnakumar, V., Hahn, M. K., & Müller, D. J. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-017-0820-z · Cited by 79 · cited 1×
“More recent results have also pointed to a role of the gut microbiome in the etiology of schizophrenia and in antipsychotic treatment outcomes, which warrants further investigation (Kanji et al., 2017).”
ResultSelf-citationFernandez-Egea, E., García-Rizo, C., Miller, B., Parellada, E., Justicia, A., Bernardo, M., & Kirkpatrick, B. (2011) · Psychosomatic Medicine · doi:10.1097/psy.0b013e318230343f · Cited by 43
Cited by
Pillinger, T., McCutcheon, R. A., Vano, L., Mizuno, Y., Arumuham, A., Hindley, G., Beck, K., Natesan, S., Efthimiou, O., Cipriani, A., et al. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30416-x · Cited by 1,090
Verhaegen, A. A., & Van Gaal, L. F. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00419-5 · Cited by 53
de Almeida, V., Alexandrino, G. L., Aquino, A., Gomes, A. F., Murgu, M., Dobrowolny, H., Guest, P. C., Steiner, J., & Martins-de-Souza, D. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109945 · Cited by 39
De, R., Smith, E. C. C., Navagnanavel, J., Au, E., Maksyutynska, K., Papoulias, M., Singh, R., Panganiban, K. J., Humber, B., Mohr, G. H., et al. (2025) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13758 · Cited by 39
Self-citationMono-ubiquitination of Rabphilin 3A by UBE3A serves a non-degradative function
Avagliano Trezza, R., Punt, A. M., Mientjes, E., van den Berg, M., Zampeta, F. I., de Graaf, I. J., van der Weegen, Y., Demmers, J. A. A., Elgersma, Y., & Distel, B. (2021) · Scientific Reports · doi:10.1038/s41598-021-82319-9 · Cited by 16
Metadata
- Authors
- Raben, A. T., Marshe, V. S., Chintoh, A., Gorbovskaya, I., Müller, D. J., & Hahn, M. K.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2018-01-22
- Volume
- 11
- Pages
- 741-741
- ISSN
- 1662-453X (ISSN-L)
- OpenAlex
- W2789176396
- Cited by
- 113
- References
- 12
- FWCI
- 2.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.